Millendo Therapeutics, Inc. OVAS Income Statement

Millendo therapeutics, inc. (OVAS)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11
Revenues
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenues
-	-	-	-	-	-	-	-	-	-	-	-	570	-	689	567	408	-	120	45	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Operating expenses:
Research and development
29,179	27,843	24,078	20,641	17,860	14,425	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs of revenues
-	-	-	-	-	-	-	-	-	-	2,005	3,535	4,494	5,401	5,126	4,507	3,390	2,249	1,091	151	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
-	-	-	-	-	-	-	-	-	-	19,486	20,460	21,450	21,641	21,599	20,607	18,641	18,433	21,039	22,366	22,879	21,784	21,795	19,732	17,774	15,802	10,949	9,282	8,057	6,323	4,296	0	0	-	0	-
Selling, general and administrative
-	-	-	-	-	-	-	-	-	-	33,883	41,439	41,898	49,223	52,848	53,145	55,002	51,594	48,038	42,203	34,197	26,149	18,796	15,167	0	-	0	0	-	-	-	-	-	-	-	-
Restructuring
-	-	-	-	-	-	-	-	-	-	9,241	8,880	6,888	5,400	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
17,698	17,556	14,426	13,918	11,525	8,691	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	6,102	4,947	3,474	0	0	0
Total costs and expenses
-	-	-	-	-	-	-	-	-	-	64,615	74,314	74,730	81,665	79,573	78,259	77,033	72,276	70,168	64,720	57,111	47,933	40,657	35,183	31,609	29,134	22,330	18,525	15,738	13,529	10,760	8,414	5,590	0	0	0
Loss from operations
-46,877	-45,399	-42,262	-38,317	-33,143	-26,874	-59,583	-61,183	-74,127	-84,326	-64,291	-73,849	-74,160	-81,012	-78,884	-77,692	-76,625	-71,999	-70,048	-64,675	-57,096	-47,933	-40,657	-35,183	-31,609	-29,134	-22,330	-18,525	-15,738	-13,529	-10,760	-8,414	-5,590	0	0	0
Other expenses:
Interest expense (income), net
885	1,038	771	479	172	-134	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other loss
-208	-207	-236	-148	-186	-169	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-46,200	-44,568	-41,727	-37,986	-33,157	-27,177	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (income) loss attributable to noncontrolling interest
-	-	-	-	-	15	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income, net
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	-	-	0	0	0	-	-	-	-	-	-	-
Interest (expense) income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	0	-	-	-	-	-
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-120	-150	-197	-164	-133	-75	-81	-20	115	114	166	122	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Loss from equity method investment
-	-	-	-	-	-	-	-	-	-	-1,386	-1,610	-1,572	-1,542	-1,556	-1,508	-1,481	-1,561	-1,844	-2,051	-1,957	-1,583	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Loss before income taxes
-	-	-	-	-	-	-	-	-	-	-65,074	-74,917	-75,262	-82,059	-79,926	-78,649	-77,621	-73,144	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense
-	-	-	-	-	-	-	-	-	-	17	98	135	201	292	200	150	75	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common stockholders
-	-	-42,418	-38,322	-	-27,192	-58,773	-60,604	-73,944	-84,578	-65,091	-75,015	-75,397	-82,260	-80,218	-78,849	-77,771	-73,219	-71,508	-66,509	-58,912	-49,520	-41,630	-35,598	-31,701	-29,044	-22,236	-18,463	-15,701	-13,510	-10,758	-8,414	-5,590	0	0	0
Net loss per share of common stock, basic and diluted (in USD per share)
-0.65	-0.86	-0.87	-0.74	-0.78	5.85	-10.61	-6.82	-6.00	-320.62	-0.26	-0.51	-0.42	-0.60	-0.54	-0.62	-0.80	-0.75	-0.66	-0.64	-0.65	-0.82	-0.54	-0.42	-0.41	-0.65	-0.40	-0.36	-0.39	2.32	-0.42	-2.09	-2.14	-1.33	-0.89	-0.78
Weighted-average shares of common stock outstanding, basic and diluted (in shares)
18,448	14,668	13,420	13,379	13,357	4,057	710	710	710	-105,941	35,687	35,664	35,642	35,687	35,568	30,036	27,301	27,287	27,267	27,198	26,588	24,062	23,766	23,546	19,214	17,378	17,048	16,869	13,345	12,871	7,438	1,548	1,383	1,222	979	526
Other comprehensive income (loss):
Foreign currency translation adjustment
-16	17	57	85	112	140	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss
0	-	-42,361	-38,237	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive income attributable to noncontrolling interest
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Comprehensive loss attributable to Millendo Therapeutics, Inc.
-	-	-42,351	-38,230	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of convertible preferred stock to redemption value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15,701	-13,510	-10,758	-8,515	-5,691	0	0	0
Net loss
-	-	-42,418	-38,322	-	-27,192	-58,773	-60,604	-73,944	-84,578	-65,091	-75,015	-75,397	-82,260	-80,218	-78,849	-77,771	-73,219	0	0	0	-	-41,630	-35,598	-31,701	-29,044	-22,236	-18,463	-15,701	-13,510	-10,758	-8,414	-5,590	0	0	0
Unrealized gains on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	0	-58	-52	110	50	103	-6	-144	-58	-96	2	-36	-17	28	-4	16	0	0	0	-	-	-	-	-	-	-
Comprehensive loss
-	-	-	-	-	-	-	-	-	-	-65,091	-75,073	-75,449	-82,150	-80,168	-78,746	-77,777	-73,363	-71,566	-66,605	-58,910	-49,556	-41,647	-35,570	-31,705	-29,028	-22,233	-18,489	-15,700	-13,516	-10,758	-8,414	-5,590	0	0	0
Stock-based compensation expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,353	3,034	1,960	1,382	0	0	0	-	-	-